Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C4 | P17516 | 1/20 | 0.66 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.66 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17613040 | 0.96 | AKR1C4 (0.62) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| SCHEMBL11988493 | 0.96 | AKR1C4 (0.71) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| SCHEMBL2702587 | 0.95 | AKR1C4 (0.60) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| SCHEMBL10022805 | 0.90 | AKR1C4 (0.66) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| SCHEMBL13741734 | 0.89 | AKR1C4 (0.62) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| SCHEMBL10022801 | 0.89 | AKR1C4 (0.53) | AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL11751123 | 0.88 | AKR1C4 (0.71) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| SCHEMBL21953399 | 0.88 | AKR1C4 (0.71) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| SCHEMBL11751129 | 0.88 | AKR1C4 (0.71) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| SCHEMBL29785187 | 0.88 | AKR1C4 (0.71) | AKR1C4AKR1C3AKR1C2HTTPTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083529-A1 | USE OF JASMONATE ESTER DERIVATIVES FOR TREATING BENIGN HYPERPROLIFERATIVE SKIN DISORDERS | SEPAL PHARMA LTD (IL) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083529-A1 | USE OF JASMONATE ESTER DERIVATIVES FOR TREATING BENIGN HYPERPROLIFERATIVE SKIN DISORDERS | MYC, KRT18, DGKK | AKR1C4 390/4885AKR1C3 401/4885AKR1C2 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.